ANTHEIA

View full entity profile (contributions, contracts, SEC) →

Lobbying Spend

—

Filings

Firms Hired

Active Period

2020–2026

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2026	—	2	1
2025	—	4	1
2024	—	4	1
2023	—	4	1
2022	—	4	1
2021	—	4	1
2020	—	3	1

Hired Firms

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
INVARIANT LLC	—	25

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
HOUSE OF REPRESENTATIVES	18
SENATE	18
Health & Human Services, Dept of (HHS)	11
Executive Office of the President (EOP)	6
Defense, Dept of (DOD)	2
Export-Import Bank of the United States (EXIM Bank)	2
Food & Drug Administration (FDA)	2
Natl Economic Council (NEC)	2
Office of Science & Technology Policy (OSTP)	2
Office of Management & Budget (OMB)	1
Office of Policy Development	1

Top Issues

Most frequently reported lobbying issues

Issue Code	Description	Reports
Health Issues	Health Issues	19
Defense	Defense	10

Bills Explicitly Cited (1)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

S. 1260117th Congress

United States Innovation and Competition Act of 2021

2021 · second_quarter · Firm: INVARIANT LLC

Open original LDA filing ↗

Cited source text and reported amounts

Highlight Antheia's use of synthetic biology to produce active pharmaceutical ingredients. Encourage support for federal loan programs for technology to strengthen our domestic supply chain for pharmaceuticals and S. 1260, United States Innovation and Competition Act of 2021.

Client expense: — · Firm income: $60,000

Matched citations: S. 1260

Source: Senate LDA

ANTHEIA — Lobbying Disclosure | Poliscope